- UroToday Home
- Recent Abstracts
- Urologic Oncology
Bladder Cancer
MTAP protein status is highly concordant with CDKN2A fluorescent in situ hybridization and allows stratification of the luminal subtype in muscle-invasive bladder cancer.
September 30, 2024
Young age and adequate BCG are key factors for optimal BCG treatment efficacy in non-muscle-invasive bladder cancer.
September 30, 2024
Real-word outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial.
September 27, 2024
Bladder cancer incidence and mortality among men with and without castration therapy for prostate cancer - a nation-wide cohort study.
September 27, 2024
Improved bladder diagnostics using multiparametric ultrasound.
September 27, 2024
An overview of immune checkpoint inhibitor toxicities in bladder cancer.
September 26, 2024
Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States.
September 25, 2024
Clinical use of nadofaragene firadenovec-vncg.
September 25, 2024
Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer: a systematic review.
September 23, 2024
HLA-E and NKG2A Mediate Resistance to M. bovis BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer.
September 23, 2024
APPRAISE-AI Tool for Quantitative Evaluation of AI Studies for Clinical Decision Support.
September 21, 2024
TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods.
September 21, 2024
Diagnostic accuracy of cytology and urine methylation test in patients with non-muscle invasive bladder cancer: a systematic review and meta-analysis.
September 20, 2024
Investigating the association between blue light cystoscopy utilization and social determinants of health.
September 20, 2024
Adjuvant immunotherapy in high-risk muscle invasive urothelial carcinoma: A systematic review and meta-analysis of randomized clinical trials.
September 20, 2024